James Lee, MD

Clinical Fellow
Medicine
Email: 

I have a research focus in adoptive T cell therapy using chimeric antigen receptors (CARs) and checkpoint inhibitors. My current interest is on the design of next generation of CARs and combination checkpoint immunotherapy in the setting of a tolerant/suppressive tumor microenvironment in solid malignancies.

Translating recent advancements in cellular cancer immunotherapy to metastatic solid tumors has been especially challenging, and this is highlighted by the lack clinical response outside of the CD19 ideal antigen as target. Current forms of therapy is likely insufficient to overcome the naturally tolerogenic microenvironment evolved to protect against autoimmunity across organ sites. Using the liver as a model organ of immune tolerance, we discovered the putative mechanisms of tumor escape to checkpoint inhibitor therapy in the setting of liver metastases and are now working on developing strategies to overcome them.

My hope is to see cancer immunotherapeutics become a mainstream form treatment that is capable of providing durable and curative responses for stage IV cancers.

Past Professional Experience:

Clinical Instructor, Memorial Sloan-Kettering Cancer Center, New York, NY. July 2012-July 2013

Clinical Instructor, University of California, San Francisco, CA. July 2013-July 2014

Education:

Medical School: Yale School of Medicine, New Haven, CT. September 2003-May 2009

Research Fellowship: Memorial Sloan-Kettering Cancer Center, New York, NY. 2006-2009.

Residency: Mount Sinai Medical Center, New York, NY. July 2009-June 2012

ABIM Board Certifications:

Internal Medicine. 2012

Medical Oncology. 2021

Publications: 

ATF7ip Targets Transposable Elements for H3K9me3 Deposition to Modify CD8+ T Cell Effector and Memory Responses.

Journal of immunology (Baltimore, Md. : 1950)

Sin JH, Kashyap S, Acenas D, Cortez JT, Lee J, Marson A, Matloubian M, Waterfield MR

Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy.

Cellular & molecular immunology

Huppert LA, Green MD, Kim L, Chow C, Leyfman Y, Daud AI, Lee JC

The Liver-Immunity Nexus and Cancer Immunotherapy.

Clinical cancer research : an official journal of the American Association for Cancer Research

Lee JC, Green MD, Huppert LA, Chow C, Pierce RH, Daud AI

Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis.

Science immunology

Lee JC, Mehdizadeh S, Smith J, Young A, Mufazalov IA, Mowery CT, Daud A, Bluestone JA

Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma.

Annals of surgical oncology

Levine LS, Mahuron KM, Tsai KK, Wu C, Mattis DM, Pauli ML, Oglesby A, Lee JC, Spitzer MH, Krummel MF, Algazi AP, Rosenblum MD, Alvarado M, Daud AI

Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer.

Cancer immunology, immunotherapy : CII

Chen YL, Huang WC, Lin FM, Hsieh HB, Hsieh CH, Hsieh RK, Chen KW, Yen MH, Lee J, Su S, Marfatia T, Chang SE, Sundar P, Patterson B, Watson D, Mei R, Javey M

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.

Diabetes

Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC

Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy.

JCI insight

Loo K, Tsai KK, Mahuron K, Liu J, Pauli ML, Sandoval PM, Nosrati A, Lee J, Chen L, Hwang J, Levine LS, Krummel MF, Algazi AP, Pampaloni M, Alvarado MD, Rosenblum MD, Daud AI

Shifting the Evolving CAR T Cell Platform into Higher Gear.

Cancer cell

Holohan DR, Lee JC, Bluestone JA

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

Blood.

Lee JC*, Pegram HJ*, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ

Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase.

Nature medicine

Santos EB, Yeh R, Lee J, Nikhamin Y, Punzalan B, Punzalan B, La Perle K, Larson SM, Sadelain M, Brentjens RJ

Inventing New CARs: Analysis of Chimeric Antigen Receptor Gene-Targeted T cells Modified to Overcome Regulatory T cell Suppression in the Tumor Microenvironment. Yale University MD Thesis. 2009

Inventing New CARs: Analysis of Chimeric Antigen Receptor Gene-Targeted T cells Modified to Overcome Regulatory T cell Suppression in the Tumor Microenvironment. Yale University MD Thesis. 2009.

Retroviral transduction of murine primary T lymphocytes.

Methods in molecular biology (Clifton, N.J.)

Lee J, Sadelain M, Brentjens R